You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

lobaplatin

Showing 1 - 25 of 46
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Triple Negative Breast Cancer Trial in Beijing (Eribulin Mesylate, Lobaplatin)

Recruiting
  • Triple Negative Breast Cancer
  • Eribulin Mesylate
  • Lobaplatin
  • Beijing, Beijing, China
    Cancer Hospital Chinese Academy of Medical Sciences
Sep 15, 2022

Hepatocellular Carcinoma Resectable Trial in Guangzhou (Oxaliplatin, Doxorubicin, Lobaplatin)

Recruiting
  • Hepatocellular Carcinoma Resectable
  • Guangzhou, Guangdong, China
    Zhujiang Hospital of Southern Medical University
Mar 1, 2023

Liver, Cancer of, Primary Resectable Trial in Guangzhou (Oxaliplatin, Doxorubicin, Lobaplatin)

Recruiting
  • Liver, Cancer of, Primary Resectable
  • Guangzhou, Guangdong, China
    Zhujiang Hospital of Southern Medical University
Jan 18, 2023

Colorectal Cancer, Chemo Effect, Surgery Trial (Mitomycin, Lobaplatin)

Not yet recruiting
  • Colorectal Cancer
  • +4 more
  • (no location specified)
Feb 18, 2022

Gastric Cancer, Chemo Effect, Surgery Trial in Wuhan (Paclitaxel, Lobaplatin)

Recruiting
  • Gastric Cancer
  • +4 more
  • Wuhan, Hubei, China
    Wuhan Union Hospital
Feb 18, 2022

Nasopharyngeal Carcinoma, Leucogen, Chemo Trial in Guangzhou (5-fu, Lobaplatin, Placebo)

Not yet recruiting
  • Nasopharyngeal Carcinoma
  • +3 more
  • Guangzhou, Guangdong, China
    Department of Radiation Oncology, Sun Yat-Sen University Cancer
Mar 10, 2023

Ovarian Cancer, Ovary Tumor, Ovarian Tumors Trial in Wuhan (HIPEC, CRS, IVCT)

Active, not recruiting
  • Ovarian Cancer
  • +5 more
  • HIPEC
  • +2 more
  • Wuhan, Hubei, China
    Zhongnan Hospital of Wuhan University
May 28, 2020

Small-cell Lung Cancer Trial in Guiyang (irinotecan plus lobaplatin, irinotecan)

Unknown status
  • Small-cell Lung Cancer
  • Guiyang, Guizhou, China
    The affiliated hospital of Guizhou medical university
Feb 3, 2020

Small-cell Lung Cancer Trial in Guiyang (etoposide plus lobaplatin, etoposide plus cisplatin)

Unknown status
  • Small-cell Lung Cancer
  • etoposide plus lobaplatin
  • etoposide plus cisplatin
  • Guiyang, Guizhou, China
    The affiliated hospital of Guizhou medical university
Feb 3, 2020

Esophageal Cancer Trial in ZhengZhou (Lobaplatin, Cisplatin)

Completed
  • Esophageal Cancer
  • ZhengZhou, Henan, China
    Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
Aug 26, 2020

Small Cell Lung Carcinoma Trial in Guangzhou (Anlotinib Hydrochloride, Lobaplatin, Etoposide)

Unknown status
  • Small Cell Lung Carcinoma
  • Anlotinib Hydrochloride
  • +2 more
  • Guangzhou, Guangdong, China
    The First Affiliated Hospital of Guangzhou Medical University
Nov 26, 2019

Ovarian Cancer Trial in Xiamen (Organoid culture)

Recruiting
  • Ovarian Cancer
  • Organoid culture
  • Xiamen, Fujian, China
    First Affiliated Hospital of Xiamen University
Apr 3, 2023

Hepatocellular Carcinoma, Portal Vein Occlusion, Tumor Thrombus Trial in Guangzhou (TACE combined with iodine-125 seeds

Active, not recruiting
  • Hepatocellular Carcinoma
  • +2 more
  • TACE combined with iodine-125 seeds implantation
  • TACE
  • Guangzhou, Guangdong, China
    The 2nd Affiliated Hospital of Guangzhou Medical University
Mar 2, 2022

Huge Hepatocellular Carcinoma (HCC) (=10cm) Trial in Beijing (GSMs-TACE, Surgical Resection)

Unknown status
  • Huge Hepatocellular Carcinoma (HCC) (≥10cm)
  • GSMs-TACE
  • Surgical Resection
  • Beijing, China
    Beijing Tsinghua Changgung Hospital
Nov 26, 2020

Nasopharyngeal Tumors Trial in Guangzhou (Tis-U-Sol)

Not yet recruiting
  • Nasopharyngeal Neoplasms
  • Guangzhou, Guangdong, China
    Affiliated Cancer Hospital & Institute of Guangzhou Medical Univ
Jun 3, 2021

Extensive Stage Small Cell Lung Cancer Trial in Fuzhou (Fluzoparil, Anlotinib)

Not yet recruiting
  • Extensive Stage Small Cell Lung Cancer
  • Fuzhou, Fujain, China
    Liu Zhenhua. ZhuangWu
Jun 17, 2021

Acute Toxic Effects, Tumor Responses Trial in Zhuhai (Lobaplatin, linear accelerator)

Completed
  • Acute Toxic Effects
  • Tumor Responses
  • Lobaplatin
  • linear accelerator
  • Zhuhai, Guangdong, China
    the Fifth Hospital Affiliated to Sun Yat-Sen University
Apr 7, 2018

Platinum Plus Low-dose Long-term Continuous Intravenous Infused

Recruiting
  • Nasopharyngeal Carcinoma
    • Guangzhou, Guangdong, China
      Department of Radiation Oncology, Sun Yat-Sen University Cancer
    Feb 18, 2021

    Peritoneal Metastases From Gastric Cancer Trial in Wuhan (exploratory laparoscopy or laparotomy, HIPEC, Systemic chemo)

    Terminated
    • Peritoneal Metastases From Gastric Cancer
    • exploratory laparoscopy or laparotomy
    • +3 more
    • Wuhan, Hubei, China
      Wuhan University
    Mar 22, 2020

    HepatoCellular Carcinoma Trial in Foshan, Guangzhou, Kaiping (Hepatic arterial infusion chemo, Transarterial chemoembolization,

    Unknown status
    • HepatoCellular Carcinoma
    • Hepatic arterial infusion chemotherapy
    • +3 more
    • Foshan, Guangdong, China
    • +3 more
    May 12, 2020

    Ovarian Cancer, Epithelial Ovarian Cancer, Ovarian Cancer, Epithelial Trial in Wuhan (CRS+HIPEC, CRS alone)

    Recruiting
    • Ovarian Cancer
    • +4 more
    • CRS+HIPEC
    • CRS alone
    • Wuhan, Hubei, China
      Zhongnan Hospital of Wuhan University
    Sep 4, 2020

    Hepatocellular Carcinoma Non-resectable Trial in Tianjin (PD-1 mAb combined with TACE and lenvatinib)

    Unknown status
    • Hepatocellular Carcinoma Non-resectable
    • PD-1 mAb combined with TACE and lenvatinib
    • Tianjin, Tianjin, China
      Tianjin Medical University Cancer Hospital
    Feb 14, 2020

    Hepatocellular Carcinoma Trial in Guangzhou, Kaiping (TACE, PD-1 antibody, Placebos)

    Withdrawn
    • Hepatocellular Carcinoma
    • TACE
    • +2 more
    • Guangzhou, Guangdong, China
    • +2 more
    Apr 30, 2019

    Hepatocellular Carcinoma Trial in Guangzhou, Kaiping (Lenvatinib, PD-1 antibody, TACE)

    Withdrawn
    • Hepatocellular Carcinoma
    • Guangzhou, Guangdong, China
    • +2 more
    Apr 30, 2019

    Hepatocellular Carcinoma Trial in Guangzhou (Embolization, Infusion of anticancer agent, Infusion of mixture of anticancer agent

    Completed
    • Hepatocellular Carcinoma
    • Embolization
    • +2 more
    • Guangzhou, Guangdong, China
      Cancer Center Sun Yat-sen University
    Mar 5, 2019